TY - JOUR
T1 - Improve hip fracture outcome in the elderly patient (iHOPE)
T2 - a study protocol for a pragmatic, multicentre randomised controlled trial to test the efficacy of spinal versus general anaesthesia
AU - iHOPE study group
AU - Kowark, Ana
AU - Adam, Christian
AU - Ahrens, Jörg
AU - Bajbouj, Malek
AU - Bollheimer, Cornelius
AU - Borowski, Matthias
AU - Dodel, Richard
AU - Dolch, Michael
AU - Hachenberg, Thomas
AU - Henzler, Dietrich
AU - Hildebrand, Frank
AU - Hilgers, Ralf-Dieter
AU - Hoeft, Andreas
AU - Isfort, Susanne
AU - Kienbaum, Peter
AU - Knobe, Mathias
AU - Knuefermann, Pascal
AU - Kranke, Peter
AU - Laufenberg-Feldmann, Rita
AU - Nau, Carla
AU - Neuman, Mark D
AU - Olotu, Cynthia
AU - Rex, Christopher
AU - Rossaint, Rolf
AU - Sanders, Robert D
AU - Schmidt, Rene
AU - Schneider, Frank
AU - Siebert, Hartmut
AU - Skorning, Max
AU - Spies, Claudia
AU - Vicent, Oliver
AU - Wappler, Frank
AU - Wirtz, Dieter Christian
AU - Wittmann, Maria
AU - Zacharowski, Kai
AU - Zarbock, Alexander
AU - Coburn, Mark
N1 - © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2018/10/18
Y1 - 2018/10/18
N2 - INTRODUCTION: Hip fracture surgery is associated with high in-hospital and 30-day mortality rates and serious adverse patient outcomes. Evidence from randomised controlled trials regarding effectiveness of spinal versus general anaesthesia on patient-centred outcomes after hip fracture surgery is sparse.METHODS AND ANALYSIS: The iHOPE study is a pragmatic national, multicentre, randomised controlled, open-label clinical trial with a two-arm parallel group design. In total, 1032 patients with hip fracture (>65 years) will be randomised in an intended 1:1 allocation ratio to receive spinal anaesthesia (n=516) or general anaesthesia (n=516). Outcome assessment will occur in a blinded manner after hospital discharge and inhospital. The primary endpoint will be assessed by telephone interview and comprises the time to the first occurring event of the binary composite outcome of all-cause mortality or new-onset serious cardiac and pulmonary complications within 30 postoperative days. In-hospital secondary endpoints, assessed via in-person interviews and medical record review, include mortality, perioperative adverse events, delirium, satisfaction, walking independently, length of hospital stay and discharge destination. Telephone interviews will be performed for long-term endpoints (all-cause mortality, independence in walking, chronic pain, ability to return home cognitive function and overall health and disability) at postoperative day 30±3, 180±45 and 365±60. ETHICS AND DISSEMINATION: iHOPE has been approved by the leading Ethics Committee of the Medical Faculty of the RWTH Aachen University on 14 March 2018 (EK 022/18). Approval from all other involved local Ethical Committees was subsequently requested and obtained. Study started in April 2018 with a total recruitment period of 24 months. iHOPE will be disseminated via presentations at national and international scientific meetings or conferences and publication in peer-reviewed international scientific journals.TRIAL REGISTRATION NUMBER: DRKS00013644; Pre-results.
AB - INTRODUCTION: Hip fracture surgery is associated with high in-hospital and 30-day mortality rates and serious adverse patient outcomes. Evidence from randomised controlled trials regarding effectiveness of spinal versus general anaesthesia on patient-centred outcomes after hip fracture surgery is sparse.METHODS AND ANALYSIS: The iHOPE study is a pragmatic national, multicentre, randomised controlled, open-label clinical trial with a two-arm parallel group design. In total, 1032 patients with hip fracture (>65 years) will be randomised in an intended 1:1 allocation ratio to receive spinal anaesthesia (n=516) or general anaesthesia (n=516). Outcome assessment will occur in a blinded manner after hospital discharge and inhospital. The primary endpoint will be assessed by telephone interview and comprises the time to the first occurring event of the binary composite outcome of all-cause mortality or new-onset serious cardiac and pulmonary complications within 30 postoperative days. In-hospital secondary endpoints, assessed via in-person interviews and medical record review, include mortality, perioperative adverse events, delirium, satisfaction, walking independently, length of hospital stay and discharge destination. Telephone interviews will be performed for long-term endpoints (all-cause mortality, independence in walking, chronic pain, ability to return home cognitive function and overall health and disability) at postoperative day 30±3, 180±45 and 365±60. ETHICS AND DISSEMINATION: iHOPE has been approved by the leading Ethics Committee of the Medical Faculty of the RWTH Aachen University on 14 March 2018 (EK 022/18). Approval from all other involved local Ethical Committees was subsequently requested and obtained. Study started in April 2018 with a total recruitment period of 24 months. iHOPE will be disseminated via presentations at national and international scientific meetings or conferences and publication in peer-reviewed international scientific journals.TRIAL REGISTRATION NUMBER: DRKS00013644; Pre-results.
U2 - 10.1136/bmjopen-2018-023609
DO - 10.1136/bmjopen-2018-023609
M3 - Journal articles
C2 - 30341135
SN - 2044-6055
VL - 8
SP - e023609
JO - BMJ Open
JF - BMJ Open
IS - 10
ER -